A Study to Assess the Effectiveness of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH)
Recruiting now
Conditions studied: HER2-positive Breast Cancer, HER2-low Breast Cancer, Breast Cancer, Advanced Cancer
In brief
This multi-center observational prospective study will collect real-world clinical and patient-reported outcome data from eligible patients with unresectable or metastatic HER2+ breast cancer who have received one or more prior anti-HER2-based regimens or patients with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+, ISH-) breast cancer who have received at least a prior systemic therapy in the metastatic setting, or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy.
Key facts
- Study ID
- NCT06210776
- Run by
- Daiichi Sankyo
- People needed
- 800
- Starts
- 2024-01-15
- Expected to finish
- 2028-03-01
- Last updated by the study team
- 2026-01-12
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Shanxi Provincial Cancer Hospital — Taiyuan, China (enrolling)
- Tangshan People's Hospital — Tangshan, China (enrolling)
- Fujian Cancer Hospital — Fuzhou, China (enrolling)
- Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen Center — Shenzhen, China (enrolling)
- The First People's Hospital of Foshan — Foshan, China (enrolling)
- Zhejiang Cancer Hospital — Hangzhou, China (enrolling)
- Harbin Medical University Cancer Hospital — Harbin, China (enrolling)
- Sun Yat-sen Memorial Hospital, Sun Yat-sen University — Guangzhou, China (enrolling)
- The University of Hong Kong- Shenzhen Hospital — Shenzhen, China (enrolling)
- Hainan Cancer Hospital — Haikou, China (enrolling)
- The First People's Hospital of Lianyungang — Lianyungang, China (enrolling)
- The Second Affiliated Hospital Zhejiang University School of Medicine — Hangzhou, China (enrolling)
- Jiangxi Cancer Hospital — Nanchang, China (enrolling)
- Nanchang Third Hospital — Nanchang, China (enrolling)
- Nanjing Drum Tower Hospital — Nanjing, China (enrolling)
- Jiangsu Province Hospital — Nanjing, China (enrolling)
- The Peoples of Guangxi Zhuang Autonomous Region — Nanning, China (enrolling)
- Affiliated Hospital Of Nantong University — Nantong, China (enrolling)
- Jiamusi Cancer Hospital — Jiamusi, China (enrolling)
- Qingdao Central Hospital — Qingdao, China (enrolling)
- Fudan University Shanghai Cancer Center — Shanghai, China (enrolling)
- Changhai Hospital — Shanghai, China (enrolling)
- Cancer Hospital of Shantou University Medical College — Shantou, China (enrolling)
- Liaoning Cancer Hospital & Institute — Shenyang, China (enrolling)
- Tianjin Cancer Hospital Airport Hospital — Tianjin, China (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.